Johnson & Johnson's third-quarter 2026 earnings look terrible, until you dig into the story a little bit more.

Johnson & Johnson (NYSE: JNJ) received FDA accelerated approval for RYBREVANT FASPRO in advanced head and neck squamous cell ...

Johnson & Johnson has been dealing for years with thousands of lawsuits related to its talc-based products, which plaintiffs claim gave them cancer. This issue has somewhat affected the drugmaker's ...

Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) granted accelerated approval ...

Johnson & Johnson will spend $2 billion over the next 10 years renting a 160,000-square-foot facility at Fujifilm Diosynth's massive manufacturing complex in Holly Springs, N.C. ((Photo by Cristina ...

The lawsuits have dragged on for more than a decade but a resolution may be in sight. Johnson & Johnson has reached a proposed $5.5 billion settlement that could end 15 years of litigation over ...

Johnson & Johnson does not provide GAAP financial measures on a forward-looking basis because the company is unable to predict with reasonable certainty the ultimate outcome of legal proceedings, ...

Add Yahoo as a preferred source to see more of our stories on Google. On Sept. 29, 1982, Mary Kellerman woke up feeling sick. The 12-year-old girl from Elk Grove Village, a suburb of Chicago, asked ...

Healthcare stocks are a great place to find recession-resistant dividend stocks, including Dividend King Johnson & Johnson. With 64 consecutive years of dividend growth under its belt, not to mention ...

Monday - Friday, 6:00 - 7:00 PM ET As Wall Street navigates a jam-packed start to earnings season, CNBC's Jim Cramer explained what made shares of Johnson & Johnson rise after the company posted its ...

Johnson & Johnson's Q3 results showed the strength of the pharma business. Click here to read more about JNJ stock and why it ...